Anadys keeps strong buy rating by JMP

Anadys Pharmaceuticals, Inc. was reiterated at a strong buy rating by JMP Securities analyst Adam Cutler. The recent meeting of the European Association for the Study of the Liver supported investor enthusiasm for new hepatitis C and B virus therapies. But, an after meeting sell-off coupled with confusion about competing drugs has created a buying opportunity in the company's shares. Anadys' ANA975 is an oral prodrug of a TLR7 agonist, and Coley's Actilon is an injectable TLR9 agonist. As the treatment and development landscape for hepatitis B virus starts to crowd, JMP believes ANA380 can be a commercial success. Shares of the San Diego biopharmaceutical company were up 10 cents, or 0.77%, at $13.09 on volume of 1,039,827 shares versus the three-month running average of 250,752 shares. (Nasdaq: ANDS)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.